INTRODUCTION
In 1953, Kidd 1 observed that guinea pig serum, but not rabbit or horse serum, could induce regression of transplanted mouse lymphoma cells in vivo. In the 1960s, evidence emerged that the Lasparaginase (L-Asp) activity of guinea pig serum was responsible for the anti-lymphoma effect. 2 This experimental work paved the way for the subsequent clinical trial in which L-Asp was shown to be an active agent in children with relapsed acute lymphoblastic leukaemia (ALL). 3 L-Asp has been a standard component of paediatric ALL regimens since the 1980s and is usually combined with a corticosteroid, vincristine and intrathecal chemotherapy in induction for both paediatric and adult patients. 4, 5 Dramatic improvements in the 5-year survival for children with ALL have been seen over recent decades, while the overall survival in adults has also improved, it remains much lower than in children. 5, 6 Outcome has continued to improve without the introduction of novel agents, with large randomised clinical trial data identifying aggressive central nervous system (CNS) prophylaxis and treatment, early post-induction intensification and increased intensity of non-myelotoxic agents as the key factors. 7 The inclusion of L-Asp therapy has clearly played an important role and there is evidence to suggest a direct relationship between outcome in ALL and L-Asp dose intensity. 8 The preparations of L-Asp used in the treatment of ALL are enzymes derived from the bacteria Escherichia coli (E. coli) and Erwinia chrysanthemi. 9 Three product types are currently available: native E. coli asparaginase, a pegylated form of the native E. coli asparaginase (polyethylene glycol-asparaginase) and Erwinia asparaginase (Erwinase).
Thrombosis is a complication associated with ALL and its therapy in both paediatric and adult practice, and represents a potentially reversible cause of morbidity and mortality. 10 L-Asp is known to increase the thrombotic risk in patients with ALL, particularly in adults. This review discusses the clinical evidence for this association and explores the available laboratory evidence to explain the underlying mechanism.
EPIDEMIOLOGY
The pathogenesis of thrombosis in ALL is likely to be therapeutically related, for thrombosis rarely occurs at presentation, with the majority of events occurring during remission induction. 10 Thrombosis is uncommon in children but the reported incidence in those receiving therapy for ALL ranges from 1.7 to 36.7%, depending on study design, treatment protocol and whether asymptomatic events are included. 10, 11 The PARKAA (Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase) study reported a prevalence rate of thrombosis of 36.7% in 60 children during induction; however, the vast majority were asymptomatic, being diagnosed during extensive screening. 12 The prevalence of symptomatic thrombosis was 5%. A meta-analysis of 17 prospective studies including 1752 paediatric patients found the incidence of symptomatic thrombosis to be 5.2%, with the majority of events occurring during induction. 13 An incidence of 4.8% was observed in the 1280 patients receiving varying doses of L-Asp. A considerable number given the estimated annual incidence of venous thrombosis in the paediatric population is 0.001%. 13 The incidence of symptomatic thrombosis appears to be higher in adult patients. A prospective study of 548 patients treated on Dana-Farber Cancer Institute (DFCI) ALL consortium protocols including L-Asp diagnosed a total of 48 symptomatic clots in 43 patients. 11 Overall, 5% (27) of 501 paediatric patients and 34% (16) of 47 adult patients experienced thrombotic events during treatment phases that included L-Asp. However, in this cohort the majority of events occurred post-induction with a median time of 3.5 months (0.5-10.1) from initiation of therapy to thrombosis.
A retrospective review of 54 adult patients treated consecutively with L-Asp containing regimens found an incidence of 18.5% symptomatic, objectively confirmed events during induction. 14 Caruso et al. 15 published results of a meta-analysis of 13 prospective studies involving 323 adults with ALL, which collectively identified a 5.9% incidence of thrombotic events during induction.
There are no randomised controlled trials to allow accurate assessment of the risk directly attributable to L-Asp therapy in ALL, but it is notable that no episodes of thrombosis were reported in a series of 204 adult patients treated with the intensive, multiagent chemotherapy regimen Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin and Dexamethasone (hyper-CVAD), which does not include L-Asp. 16 
SITES OF THROMBOSIS
The majority of events occurring in association with L-Asp are venous, but arterial thrombosis is reported. 10, 17 The PARKAA study of L-Asp-treated children with a central venous line (CVL), which included asymptomatic events, reported 83% (19 of 23) thromboses to occur in the upper central venous system, 13% (3) in the right atrium and 4% (1) in the CNS.
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A meta-analysis of 1752 children reported 91 events, with 53.8% (49) involving the CNS, 42.8% (39) being venous in other sites and the remainder unspecified. 13 Only 26 of the CNS events were clearly identified as being of venous origin with the others labelled as cerebral thrombosis, infarction or stroke. Of the non-CNS venous events, 64.1% (25) were identified as being CVL associated. The overall risk of a CNS event was determined as 2.9% and a non-CNS event as 2.3%. Of note, the site of event was not analysed in relation to L-Asp therapy, but the majority of events did occur in patients receiving L-Asp. No peripheral arterial events were reported. A further study in children receiving L-Asp focused only on CNS events, finding 7 symptomatic CNS thromboses in 719 patients, giving an overall rate of 1%. 18 The more recently published data from both adult and paediatric patients treated according to DFCI consortium protocols identified 47 venous events, with 36% (17) being upper extremity/CVL related, 19% (9) lower extremity, 19% (9) CNS and 15% (7) pulmonary embolism. 11 The remainder were described as intra-cardiac (2%) and 'other' (8.5%). The sites of event were similar across adult and paediatric patients, but with a tendency for adults to experience more pulmonary embolism and children more CNS events.
A meta-analysis of adult studies involving 323 patients with 19 events found deep vein thrombosis originating in the lower limbs the most common site (38.9%) with no arterial events. 15 
EFFECT OF L-ASP PREPARATION ON THROMBOSIS
L-Asp is a universal component of paediatric regimens used to treat ALL and is more often than not included in adult regimens. However, the debate over the optimal preparation and dosage continues. Two large randomised studies have shown superior efficacy for E. coli L-Asp when compared with Erwinia L-Asp in terms of complete remission rate, relapse rate and overall survival, but at the expense of increased toxicity. 19, 20 Erwinia L-Asp is often used as a second-or third-line agent in patients developing hypersensitivity to E. coli L-Asp preparations. Erwinia L-Asp has also been linked to thrombosis in the literature but population sizes have been small and doses given often differ from those currently recommended. 21, 22 There was no difference in CNS thrombosis in a randomised comparison of native E. coli L-Asp and polyethylene glycol-L-Asp in a study of 118 children, with 2 (3.4%) events in each arm. 23 Children treated on the DFCI consortium protocol 05-01 received a single dose of intravenous polyethylene glycol-L-Asp and venous thrombotic events occurred in 4 (2%) of patients, 2 being in the CNS. 24 
EFFECT OF CORTICOSTEROID
Corticosteroids are an established component of ALL therapy and are usually given in combination with L-Asp and other chemotherapeutic agents during induction. High levels of plasma corticosteroids, such as those found in patients with Cushing's syndrome, have been associated with an increased risk of thrombosis. Elevated levels of coagulation factors (F) VIII, FIX and von Willebrand's Factor (vWF) are thought to contribute to the hypercoagulable state observed in these patients. 25 Results from several in vitro studies have suggested that corticosteroids may directly activate coagulation and inhibit fibrinolysis by increasing the synthesis and secretion of vWF and plasminogen activator inhibitor-1 (PAI-1). 26 Prednisolone has been associated with an increase in FVIII, vWF and PAI-1. 27, 28 Dexamethasone has been shown to cause a modest but clear rise in the activity of FVII, FVIII, FIX and fibrinogen in healthy volunteers, but to have no significant effect on PAI-1. 29 The use of corticosteroids during inflammatory states has been consistently associated with reduced levels of vWF and fibrinogen but increased PAI-1. 26 Systemic inflammation is known to be a potent prothrombotic stimulus and the inflammatory and coagulation systems are closely linked, therefore some of the prothrombotic changes induced by corticosteroid therapy may be balanced by the anti-inflammatory actions. 26, 30, 31 There are no randomised trials comparing the thrombosis risk associated with different corticosteroids in L-Asp-exposed patients. However, a comparison of paediatric patients treated according to different Berlin-Frankfurt-Munster protocols indicated a much lower risk during induction with dexamethasone (1.8%) than with prednisolone (10.4%).
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A meta-analysis of prospective paediatric studies found a lower rate of thrombosis in those exposed to dexamethasone (2.0%) as opposed to prednisolone (4.9%) during induction, but this difference was not significant. 13 No difference in thrombosis rates was seen between patients receiving L-Asp and corticosteroids concomitantly and separately.
MECHANISM OF ACTION OF ASPARAGINASE
L-Asp catalyses the hydrolysis of L-asparagine (ASN) to L-aspartic acid and ammonia, resulting in depletion of the circulating pool of ASN. 32 Although ASN is not an essential amino acid, human lymphoblasts typically have low levels of ASN synthetase activity and are dependent on extracellular sources of ASN for protein synthesis. 33 ALL cells require significant amounts of ASN for protein synthesis to maintain rapid proliferation, with a deficiency leading to cytotoxicity. 34 ASN is required for dividing cells to proceed through the G1 phase of the cell cycle, which ensures that the cell is ready for DNA synthesis and is marked by high rates of synthesis of the enzymes required in S phase. Depletion of ASN is therefore not tolerated by dividing cells and in vitro apoptotic cell death of leukaemia cells induced by L-Asp is associated with cell-cycle arrest in the G1 phase. 35, 36 L-Asp is also known to catalyse the hydrolysis of glutamine (GLU) to glutamic acid, resulting in depletion of circulating levels of this amino acid. 37 GLU acts as a nitrogen donor for a number of enzymes involved in the de novo synthesis of purine and pyrimidine nucleotides, which are essential for the synthesis of Risk associated with L-Asp treatment in ALL adults E Truelove et al RNA and DNA in proliferating cells. 38 Furthermore, the synthesis of ASN from L-aspartic acid requires GLU as the amide donor. Adequate cellular concentrations of ASN and GLU are therefore necessary for RNA, DNA and protein synthesis in dividing cells, and by depleting the availability of these amino acids L-Asp is able to disrupt the proliferation of lymphoblasts and induce apoptosis.
EFFECT OF L-ASP ON COAGULATION SCREENING TESTS
Currently available laboratory screening tests to assess the integrity of the coagulation cascade are in vitro assays that cannot reliably replicate in vivo haemostasis and therefore have limitations. They have, however, been widely used to monitor haemostatic changes occurring during L-Asp therapy. The most commonly employed tests are the activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time and fibrinogen.
L-Asp can have profound effects on both the coagulation and fibrinolytic systems, resulting in reduced plasma levels of a number of coagulation factors, including fibrinogen, FV, FVII, FVIII, FIX, FX and FXI as well as other key elements of haemostasis. 39 The APTT, PT and thrombin time are sensitive to decreased levels of certain coagulation factors and prolongation of one or more of these clotting times is often seen.
A number of studies have demonstrated that coagulation screens in paediatric patients with ALL are sensitive to the effects of L-Asp. [40] [41] [42] The first study evaluated 26 patients during induction with vincristine, prednisolone and L-Asp and reported prolongation of the PT in 16, the APTT in 23 and the thrombin time in 21 patients. 40 All patients had reduced fibrinogen levels and all parameters returned to normal within 2 weeks of completion of L-Asp. Another study involving 13 patients during induction reported a similar pattern of results. 41 However, a study of patients exposed to single agent L-Asp once in remission reported that although clotting times were prolonged from baseline, the PT remained within normal limits and the APTT was only marginally prolonged. 42 
MECHANISMS OF THROMBOSIS
Haemostasis is a delicately balanced homeostatic process that maintains blood fluidity and also the integrity of the cardiovascular system after tissue injury by coordinating rapid and localised thrombus formation. The five major components of haemostasisthe vascular endothelium, platelets, the coagulation cascade, physiological anticoagulants and fibrinolysis-are tightly regulated under physiologic conditions, but when pathological states overwhelm these regulatory mechanisms or the mechanisms are defective, thrombosis can result. 43 The association between L-Asp and thrombosis has been attributed to reduced biosynthesis of the natural anticoagulant proteins; however, L-Asp also reduces levels of the coagulation proteins as evidenced by the fall in fibrinogen and increment in PT and APTT. This suggests that there may be a global inhibition of production of both coagulant and anticoagulant proteins in the liver, which may be exacerbated by consumption of haemostatic factors in the formation of a thrombus but does not reliably explain the mechanism of thrombosis.
There is evidence from a study of 23 children with ALL treated with the Berlin-Frankfurt-Munster protocol that thrombin generation and peak thrombin were significantly higher during induction than re-induction. 44 Interestingly, two of these patients developed deep vein thrombosis at the time of peak endogenous thrombin generation.
Physiological anticoagulants
The rapid and efficient response of the coagulation cascade to haemorrhage is achieved by serial proteolytic cleavage of circulating inactive coagulation factors, which culminates in local fibrin deposition. Most coagulation factors are serine proteases, which are regulated by serine protease inhibitors (Serpins), acting as natural anticoagulants.
Antithrombin (AT) is an important serpin, with a range of inhibitory influences on the coagulation cascade, most notably thrombin (IIa) and FXa, but also FIXa, FXIa, FXIIa, tissue plasminogen activator, urokinase, plasmin and kallikrein. 45 Patients with a heterozygous deficiency of AT have a high risk of venous thromboembolism (VTE)-as a general rule 50% will have a venous VTE before the age of 50. Low levels of AT during L-Asp therapy in childhood ALL have been reported by a number of studies. 41, 42, 46 The effect attributable to L-Asp specifically on AT levels is difficult to interpret in some series due to the failure to measure other components of the haemostatic pathway. The deficiency observed could be a manifestation of failure in hepatic synthetic function, exacerbated by consumption during thrombus formation. It is likely that the haemostatic balance of physiological anticoagulants versus coagulation factors is set at a lower level following L-Asp.
Homans et al. 42 demonstrated that AT levels were reduced to 34% of pre-treatment levels when L-Asp was given as a single agent to children with ALL in remission and returned to baseline 14 days after cessation of therapy. The DFCI protocol 87-001 evaluated the in vivo effect of single agent L-Asp on AT levels in untreated paediatric patients with ALL. Levels at presentation were similar to healthy age-matched controls, but significantly decreased after L-Asp therapy, returned to baseline after combination chemotherapy (without L-Asp) and again significantly decreased after consolidation (including L-Asp). 46 The more recent CAPELAL study in adult patients reported that median AT levels of 120% before first L-Asp infusion dropped to 59% by the fourth infusion. 47 During this study, 20 thrombotic events occurred in 9.3% of patients from 2 to 35 days after the first L-Asp infusion.
As with other serpins, AT has a structural flexibility that allows a conformational change essential to its inhibitory function on target proteases. 48 However, this feature makes serpins susceptible to conformational changes induced by amino-acid modifications in structurally sensitive regions of the molecule. Inherited AT deficiency is associated with a wide range of mutations, including those with conformational effects, which tend to have a clinically severe phenotype. 45, 48 The acquired AT deficiency induced by L-Asp can be explained by a global reduction in hepatic protein synthesis. Two groups have previously shown that L-Asp has no direct effect on mature AT in terms of antigen levels or activity, as detected by anti-FXa activity. 49, 50 These groups have also demonstrated that hepatocarcinoma (HepG2) cells treated with L-Asp show a marked reduction in AT secretion but no reduction in AT mRNA levels, suggesting interference at a post-transcriptional stage. Further experiments to assess the mechanism of L-Asp on AT secretion found intracellular accumulation of AT aggregates in HepG2 cells and observed a similar pattern in mice, with retention and aggregation of the protein within the lumen of dilated rough endoplasmic reticulum cisterns. 50 There is, however, some conflicting data within the literature, with results of an earlier study suggesting that L-Asp may have a direct effect on the AT protein and other coagulation system proteins. 51 Heparin cofactor II (HCII) is another serpin that inhibits thrombin, protease nexin 1 and C1 inhibitor. 48 Deficiency of HCII has been linked to thrombosis, but the significance of its role remains unclear. L-Asp treatment of HepG2 resulted in decreased secretion of HCII and Mitchell et al. found that HCII plasma concentrations were raised in children with ALL, but significantly decreased following therapy with L-Asp alone. 46, 49 The protein C system is the physiological pathway responsible for degrading the activated coagulation cofactors, FVa and FVIIIa, as well as reducing platelet prothrombinase activity. Protein C is activated by the thrombin-thrombomodulin (TM) complex on the Risk associated with L-Asp treatment in ALL adults E Truelove et al surface of endothelial cells and its effects are facilitated via the cofactor activity of protein S. Both protein C and S are vitamin K dependent and deficiency of either, as well as resistance to activated protein C is associated with thrombosis. 52 The administration of L-Asp as a single agent to children with ALL in remission has been associated with marked reductions in protein C antigen levels. 42 A significant decline in both protein C and free protein S occurred in paediatric patients treated with L-Asp on the DFCI protocol 87-001. 46 Two small studies in adult patients reported results consistent with the pattern seen in children, with marked reductions in the anticoagulant activities of protein C and S following L-Asp. 53, 54 Fibrinolytic system Fibrinolysis is the process by which fibrin clots are dissolved and is a requirement of normal haemostasis. The serine protease plasmin is the predominant fibrinolytic enzyme, but circulates as a proenzyme, plasminogen. Plasminogen is activated by tissue plasminogen activator, released from endothelial cells as well as by urokinase-type plasminogen activators, FXIIa and kallikrein. Plasmin generation at the site of vascular injury limits the extent of thrombus formation by directly degrading fibrin, fibrinogen, FV, FVII and FVIII. Inhibition of fibrinolysis is predominantly controlled by two serpins, PAI-1, which inhibits tissue plasminogen activator and urokinase-type plasminogen activator, and a2-antiplasmin, which inhibits plasmin. 48 Fibrinolytic parameters have been studied in L-Asp-treated ALL patients, with reduced fibrinogen levels being consistently reported. 41, 42, 47, 55 There is uncertainty whether depletion of fibrinogen is due to lack of production, generation of dysfibrinogenaemia and/or excessive fibrinolytic activity, compounded by increased consumption during thrombotic episodes. Plasminogen and a2-antiplasmin levels have also been shown to decline following L-Asp and again it is uncertain whether this reflects lack of production by the liver, increased consumption, or both. Platelets A venous thrombus usually develops in conditions of low shear or stasis and is predominantly composed of red cells and fibrin with relatively few platelets; thus, disorders affecting platelets are rarely associated with increased risk of venous thrombosis. However, the hypothesis that abnormal platelet aggregation in response to L-Asp may contribute to the associated thrombotic risk has been investigated. Increased platelet sensitivity to ADP during induction with L-Asp has been reported in one paediatric study, while another demonstrated normal platelet function studies throughout L-Asp therapy for patients in remission. 41, 42 This latter result was supported by a study of 20 children, which found no difference in aggregation with standard agonists between ALL patients and controls. 56 However, an in vitro agonist effect of L-Asp on platelets from both leukaemic patients and controls was documented, raising the possibility of a similar effect in vivo, but this remains to be demonstrated.
Endothelium
The endothelium has a vital role in the regulation of blood flow and haemostasis by generating an antithrombotic surface due to expression of TM and heparan sulphate, as well as inhibiting platelets via nitric oxide and prostacyclin (PGI 2 ). However when stimulated by agents such as interleukin 1, tumour necrosis factor or thrombin, it undergoes a transformation-known as endothelial cell activation-whereby it expresses a prothrombotic phenotype. 57 TM exerts its effect by binding with thrombin, transforming it into a highly effective anticoagulant that activates protein C and reduces platelet activation. 58 Endothelial activation results in downregulation of TM production and pinocytosis of TM on the surface of the endothelium, such that the endothelium loses its ability to activate Protein C. Other changes include expression of tissue factor (TF), cleavage of heparin sulphate (which usually potentiates AT) and increased expression of PAI-1.
L-Asp has been shown to disrupt endothelial function. P-selectin, a cell adhesion molecule, and PAI-1 have been studied in children with ALL during induction inclusive of L-Asp. 59 Levels of both were noted to be increased at diagnosis compared with controls and continued to increase during induction.
In a study of 26 children treated on the FRALLE (French Acute Lymphoblastic Leukemia) group-2000 protocol, TF activity and vWF antigen levels significantly increased with the number of L-Asp infusions during induction. 60 TM activity was also increased compared with controls but remained in the same range as values seen at diagnosis. In vitro experiments indicate that L-Asp can induce a modest increase of TF expression on lymphoblasts, whereas a marked increase was observed on endothelial cell lines. 60 These in vitro observations again support the possible role of endothelial and/or leukocyte activation in upregulation of TF during the L-Asp-associated hypercoagulable state.
PREVENTION AND MANAGEMENT OPTIONS
Management of patients being treated with L-Asp presents a considerable clinical dilemma. The APTT and PT are often prolonged in association with reduced levels of haemostatic proteins and fibrinogen but thrombosis rather than haemorrhage is the predominant problem. The thrombosis risk in adults is greater than in children receiving the drug; for adults have more prothrombotic physiological haemostasis than children, and this is compounded by additional risk factors in adults such as smoking, obesity and poor performance status leading to a higher degree of immobility.
Since thrombosis is commonly related to an indwelling CVL, it is generally recommended that their placement should be postponed until the first phase of induction therapy is complete; however, evidence to support this practice is lacking. Optimal timing for CVL insertion in patients with ALL is unknown. One retrospective study of paediatric ALL patients treated with L-Asp during induction found that early CVL placement was not associated with an increased risk of thrombosis compared with delayed insertion. 61 In addition, delayed CVL insertion is not always practical, particularly since adult therapeutic regimens often contain more doses of vesicant drugs, such as anthracyclines.
In the past, treatment protocols frequently specified that abnormalities in the coagulation screen be used to guide plasma replacement with fresh frozen plasma or cryoprecipitate. Evidence to support this recommendation is lacking and available data now argue against the practice. A paediatric study found that fresh frozen plasma replacement had no demonstrable effect on laboratory parameters of coagulation with only minimal improvements in fibrinogen. 62 A retrospective analysis of paediatric patients receiving L-Asp found that neither fresh frozen plasma nor cryoprecipitate protected against CNS thrombosis and concluded that prophylactic plasma replacement is not warranted. 18 Furthermore, there is evidence that fresh frozen plasma contains ASN, which might compromise L-Asp therapy by replenishing the ASN pool the therapy is intended to deplete. Fibrinogen concentrates are increasingly used in the management of hypofibrinogenaemia but have been associated with thrombosis, 63 and concern remains about the thrombotic potential that may be associated with their use in L-Asp-treated patients.
Thrombotic problems are much more common than haemorrhage but the presence of abnormalities of the APTT, PT and/or fibrinogen present a practical problem when patients require invasive procedures. A particular concern is lumbar puncture, since intrathecal drug administration is invariably a component of ALL management. Members of staff are reluctant to perform such Risk associated with L-Asp treatment in ALL adults E Truelove et al procedures without attempting to correct the coagulation abnormalities and this still represents an unresolved problem.
Prophylactic AT supplementation Several studies have addressed the prevention of thrombosis. AT supplementation has been explored in paediatric and adult populations during L-Asp therapy, with initial studies concluding that although enhanced thrombin generation and d-dimer levels associated with therapy returned towards normal with AT replacement, further randomised trials were required to demonstrate whether a clinical benefit existed. 54, 62 The more recent PARKAA study showed a trend towards efficacy and safety with AT concentrate in prevention of thrombosis in children treated with LAsp, but the study was not powered to answer this question. 64 The CAPELAL study reported lower rates of thrombosis in adults who received prophylactic AT concentrate (4.5%) than in those who had not (12.7%). 47 However, this was a retrospective analysis and again the authors concluded that further work is required to define the role of AT in the management of L-Asp-treated patients.
Thromboprophylaxis
Pharmacological prophylaxis to prevent hospital-acquired VTE is widely and safely used, and current guidelines recommend it be offered to medical patients assessed to be at increased risk. 65 It seems logical that use of anticoagulant agents for primary VTE prophylaxis in L-Asp-treated patients will reduce rates of thrombosis, but randomised clinical trial data are lacking. A nonrandomised study of 41 paediatric patients with ALL using the low molecular weight heparin (LMWH) enoxaparin as prophylaxis during L-Asp therapy reported no thrombotic events during 76 courses of L-Asp, with 1 brain infarct reported 7 days after cessation of prophylaxis. 66 LMWH has also been used successfully as secondary prophylaxis in patients re-exposed to L-Asp following an initial VTE without recurrence or excess bleeding. 67 However, there remains concern that heparins, which rely on AT for their mechanism of action, may not be the most appropriate option. Clinical data are again lacking but in vitro experiments using plasma from children with L-Asp-induced AT deficiency have demonstrated a consistent anticoagulant response with direct thrombin inhibitors, independent of AT levels, whereas a profound effect on the action of LMWH related to AT concentration was seen. 68 The new oral direct thrombin inhibitors and anti-Xa anticoagulants are currently being assessed in medical patients for thromboprophylaxis, and if these trials demonstrate efficacy and safety then study in L-Asp-treated patients would be warranted. It is likely that pharmacological thromboprophylaxis will have an increasing role in the management of L-Asp-exposed patients.
Management of thrombosis Management of thrombotic events requires therapeutic anticoagulation. A number of options are available. LMWH is usually preferred to vitamin K antagonists in patients receiving concurrent myelosuppressive therapy. Unfractionated heparin is preferable in those with renal failure or at a high risk of haemorrhage, who may need rapid anticoagulation reversal. Heparin is reliant on AT for its therapeutic effect and resistance may be encountered with AT deficiency engendered by L-Asp. AT monitoring and replacement may be necessary to maintain therapeutic anticoagulation with heparin and LMWH in L-Asp-treated patients. A more attractive option would be to use an anticoagulant with a direct anticoagulant effect not mediated through AT. The use of one of the new oral agents such as rivaroxaban or dabigatran is worthy of exploration in the future, although their irreversibility may limit their use.
SUMMARY
Therapy with L-Asp is associated with an increased thrombotic risk with alterations in the levels of multiple haemostatic proteins being consistently demonstrated. Although the thrombotic risk in the past has been attributed to the acquired AT deficiency-which clearly occurs, the levels of both coagulation factors and anticoagulant proteins are reduced. We suggest that while L-Asp reduces haemostatic protein production, it also seems biologically plausible that L-Asp exposure results in upregulation of TF through white cell and/or endothelial activation leading to thrombosis initiation and consumption of haemostatic proteins.
In some patients, the presence of additional risk factors including an underlying thrombophilia, sepsis, obesity, increasing age and immobility will result in an overwhelming drive to thrombosis (see Figure 1) . However, many questions remain unanswered and this area requires further study. Risk associated with L-Asp treatment in ALL adults E Truelove et al
The available evidence suggests that AT replacement may have a role in prophylaxis against L-Asp-associated thrombosis but this requires confirmation in randomised trials. It would seem logical to use pharmacological anticoagulants for prophylaxis, particularly those which do not exert their mechanism of action through AT. A detailed understanding of the thrombotic mechanism will likely be a key to defining the optimal strategy for prevention and management of L-Asp-associated thrombosis.
